Peter G. Linde

Corporate Officer/Principal presso Walden Biosciences, Inc.

57 anni

Health Technology

Finance

Health Services

Posizioni attive di Peter G. Linde

Società	Posizione	Inizio	Fine
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Corporate Officer/Principal	11/10/2022	-

Società	Posizione	Inizio	Fine
MORPHIC HOLDING, INC.	Direttore Tecnico/Scientifico/R&S	17/03/2020	31/12/2021
FIBROGEN, INC.	Corporate Officer/Principal	-	-
ACCELERON PHARMA INC.	Corporate Officer/Principal	-	-

Massachusetts Institute of Technology

Undergraduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	2
MORPHIC HOLDING, INC.	Health Technology
FIBROGEN, INC.	Health Technology

Aziende private	2
Acceleron Pharma, Inc. Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.	Health Technology
Walden Biosciences, Inc. Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA.	Health Services

Aziende private

Health Technology

Health Services